23.28
0.76 (3.40%)
| Previous Close | 22.51 |
| Open | 23.00 |
| Volume | 1,656,657 |
| Avg. Volume (3M) | 10,845,331 |
| Market Cap | 2,436,239,360 |
| Price / Earnings (Forward) | 8.67 |
| Price / Sales | 0.990 |
| Price / Book | 1.72 |
| 52 Weeks Range | |
| Earnings Date | 5 Nov 2025 |
| Profit Margin | -11.12% |
| Operating Margin (TTM) | -40.33% |
| Diluted EPS (TTM) | -2.64 |
| Quarterly Revenue Growth (YOY) | 80.20% |
| Quarterly Earnings Growth (YOY) | 248.40% |
| Total Debt/Equity (MRQ) | 118.73% |
| Current Ratio (MRQ) | 4.02 |
| Operating Cash Flow (TTM) | -547.15 M |
| Levered Free Cash Flow (TTM) | -741.26 M |
| Return on Assets (TTM) | -2.19% |
| Return on Equity (TTM) | -23.61% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Sarepta Therapeutics, Inc. | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | -3.5 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 2.0 |
| Average | -0.88 |
|
Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Majority of company's product candidates are at an early stage of development. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 4.42% |
| % Held by Institutions | 96.33% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Erste Asset Management Gmbh | 30 Jun 2025 | 1,621,415 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 50.00 (BMO Capital, 114.82%) | Buy |
| 50.00 (Wells Fargo, 114.82%) | Buy | |
| Median | 19.50 (-16.22%) | |
| Low | 5.00 (HC Wainwright & Co., -78.52%) | Sell |
| Average | 22.63 (-2.77%) | |
| Total | 5 Buy, 7 Hold, 4 Sell | |
| Avg. Price @ Call | 16.95 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| BMO Capital | 22 Sep 2025 | 50.00 (114.82%) | Buy | 18.65 |
| 29 Jul 2025 | 50.00 (114.82%) | Hold | 15.83 | |
| Guggenheim | 15 Sep 2025 | 22.00 (-5.48%) | Buy | 17.47 |
| Leerink Partners | 09 Sep 2025 | 15.00 (-35.55%) | Hold | 17.64 |
| HC Wainwright & Co. | 25 Aug 2025 | 5.00 (-78.52%) | Sell | 18.06 |
| B of A Securities | 21 Aug 2025 | 16.00 (-31.26%) | Sell | 20.06 |
| 20 Aug 2025 | 17.00 (-26.96%) | Sell | 20.58 | |
| Deutsche Bank | 15 Aug 2025 | 12.00 (-48.44%) | Sell | 21.81 |
| Goldman Sachs | 07 Aug 2025 | 19.00 (-18.37%) | Hold | 17.96 |
| Wells Fargo | 07 Aug 2025 | 50.00 (114.82%) | Buy | 17.96 |
| 24 Jul 2025 | 48.00 (106.23%) | Buy | 12.88 | |
| Barclays | 30 Jul 2025 | 22.00 (-5.48%) | Hold | 16.75 |
| 29 Jul 2025 | 22.00 (-5.48%) | Hold | 15.83 | |
| Bernstein | 29 Jul 2025 | 13.00 (-44.15%) | Hold | 15.83 |
| JP Morgan | 29 Jul 2025 | 24.00 (3.11%) | Hold | 15.83 |
| Morgan Stanley | 29 Jul 2025 | 20.00 (-14.07%) | Hold | 15.83 |
| Oppenheimer | 29 Jul 2025 | 37.00 (58.97%) | Buy | 15.83 |
| Piper Sandler | 29 Jul 2025 | 15.00 (-35.55%) | Hold | 15.83 |
| 22 Jul 2025 | 11.00 (-52.74%) | Hold | 13.62 | |
| Citigroup | 24 Jul 2025 | 7.00 (-69.92%) | Sell | 12.88 |
| Jefferies | 24 Jul 2025 | 35.00 (50.38%) | Buy | 12.88 |
| Show more | ||||
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |